subject inclusion criteria in PK and stat and BE conclusion [Regulatives / Guidelines]

posted by Ramesh Ramalingam  – India, 2017-09-05 07:35  – Posting: # 17776
Views: 6,202

Dear All,

I have more doubt on subject inclusion criteria for pharmacokinetic and statistical analysis in fully replicate (Including NTI drugs) and partial replicate design BE studies. could you please suggest the subject inclusion criteria for PK and stat analysis (including who's data can be considered for BE)? Also, How many treatment periods subject should be completed in the study?



Regards,
Ramesh Ramalingam

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,871 posts in 4,212 threads, 1,364 registered users;
online 10 (0 registered, 10 guests [including 9 identified bots]).
Forum time (Europe/Vienna): 03:26 CEST

Multivariate analysis: A means of finding the answer
when you don’t know the question.    Stephen Senn

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5